Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC

Summary

This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC. A safety introductory trial was conducted to receive LTC004 in combination with regorafenib before starting the formal trial. After completing a 28-day safety assessment, safety will be confirmed before entering the formal trial phase. Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC

Timeline

Start

2024-04-01

Primary completion

2025-03-01

Completion

2025-03-01

Drugs

Indications